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Staging of hepatocellular carcinoma (HCC) is complex and relies on multiple factors including tumor
extent and hepatic function. No single staging system is applicable to all patients with HCC. The staging
of the American Joint Committee on Cancer / International Union for Cancer Control should be used to
predict outcome following resection or liver transplantation. The Barcelona Clinic Liver Cancer scheme is
appropriate in patients with advanced HCC not candidate for surgery. Dual phase computed tomography
or magnetic resonance imaging can be used for pretreatment assessment of tumor extent but the
accuracy of these methods remains poor to characterize <1 cm lesions. Assessment of tumor response
should not rely only on tumor size and new imaging methods are available to evaluate response to therapy
in HCC patients. Liver volumetry is part of the preoperative assessment of patients with HCC candidate
for resection as it reflects liver function. Preoperative portal vein embolization is indicated in patients with
small future liver remnant ( 20% in normal liver;  40% in fibrotic or cirrhotic liver). Tumor size is not a
contraindication to liver resection. Liver resection can be proposed in selected patients with multifocal
HCC. Besides tumor extent, surgical resection of HCC may be performed in selected patients with
chronic liver disease.
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Staging of hepatocellular carcinoma
Background
The construction of an internationally accepted and preferentially
used staging system for hepatocellular carcinoma (HCC) has
proven to be a daunting task.1 Estimating prognosis for patients
with HCC is extremely complex because prognosis depends not
just on tumor related factors and the anatomic extent of disease
but also on liver function, patient factors, treatment efficacy and
interactions between them2,3 (table 1). Liver function is likely
the most important predictor of survival since the majority of
patients with HCC have end stage liver disease whereas tumor
extent and tumor directed therapy have limited influence on sur-
vival.1,4,5 In patients without, or limited, liver disease, quality and
type of treatment are more important predictors of outcome than
tumor related factors.4,6
In 1999, the European Association for Study of Liver Disease
(EASL) proposed a staging system which included four varia-
bles: anatomic tumor stage, degree of liver dysfunction, general
Proceedings of the Consensus Conference onMultidisciplinary Treatment of
Hepatocellular Carcinoma sponsored by the American Hepato-Pancreato-
BiliaryAssociation and co-sponsoredby the Society of SurgicalOncology and
the Society for Surgery of theAlimentary Tract and theUniversity of TexasM.
D. Anderson Cancer Center held in Orlando, FL, USA; January 21, 2010.
DOI:10.1111/j.1477-2574.2010.00181.x HPB
HPB 2010, 12, 289–299 © 2010 International Hepato-Pancreato-Biliary Association
condition of the patient and treatment efficacy.5 Since then, a
number of new staging systems have been developed to improve
selection for therapies and predict survival.7 However, there is no
universally accepted staging system that enables investigators to
compare treatment results across institutions and regions.8
The problem of using multiple staging systems
The first AHPBA and AJCC consensus conference on staging for
HCC in 2003 recognized that no single staging system fulfilled all
the needs of physicians treating HCC.9 The group recommended
the use of the Cancer of the Liver Italian Program (CLIP) staging
system for prognosis stratification and treatment guidance in
nonsurgical patients with advanced HCC and/or liver disease and
use of the 6th edition of the AJCC/UICC TNM for patients who
qualify for liver resection and liver transplantation. The AHPBA
consensus group agreed with the EASL expert panel that HCC
staging systems should combine liver disease, general health
and tumor factors as features of a system to provide guidance for
patient therapy, estimate prognosis, and save health care
resources.9 To date, the problems created by the use of multiple
staging systems for HCC are not resolved. At the time of the 2010
AHPBA HCC consensus conference, there were 18 HCC staging
or scoring systems in use around the world (table 2). The plethora
of staging systems is related principally to two issues. First, no
single staging system predicts accurately outcomes for all HCC
patients. Staging system performance is highly variable because it
depends upon many factors including patient demographics,
treatment, type and extent of liver disease and stage of disease.
Table 1 Predictive factors of outcome in HCC
Patient factors General medical conditions
Performance Status
Quality of life score
Tumor factors Number, size, total tumor volume
Histopathologic grade
Vascular invasion
DNA aneuploidy (DNA index)
Genotype
VEGF levels
Serum AFP
Liver factors Child Pugh score
MELD score
Fibrosis score
Active inflammation
Functional hepatic reserve
Maximal removal rate of glycolated human serum albumin (GSA-Rmax)
Protein induced by vitamin K absence/antagonism II (PIVKA-II serum levels)
Etiology of liver disease Alcohol
Hepatitis B
Hepatitis C
Interactions between patient factors, tumor factors
and treatment efficacy
Table 2 HCC Staging Systems
Clinical Okuda
IHPBA (International Hepato-Pancreato-Biliary Association)
CLIP (Cancer of the Liver Italian Programme Score)
BCLC (Barcelona Clinic Liver Cancer)
Revised BCLC
CUPI (Chinese University Prognostic Index)
American Liver Tumor Study Group modified Tumor-Node-Metastasis classification. (ALTSG)
Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (GRETCH)
Pathological staging systems American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC)
Liver Cancer Study Group of Japan (LCSGJ) staging system
Japanese Integrated Staging (JIS) score (includes the LCSGJ)
Modified JIS
New Liver Cancer Study Group of Japan TNM
Early HCC prognostic score
Tokyo score
Transplant staging systems UNOS modified TNM staging system
UCSF extended criteria
Pittsburgh scoring system
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Secondly, improved understanding of the natural history of
HCC, its response to various treatments and identification of new
biologic markers that may predict outcomes have resulted in the
rapid evolution of staging systems.
The importance of accurate tumor staging
prior to treatment
Staging HCC is difficult, thus leading to staging inaccuracies
and challenges when trying to compare treatment and study out-
comes. For instance, difficulty discriminating early HCC from
enhancing regenerative nodules smaller than 2 cm has led to some
patients being falsely labeled with HCC. Tumor related factors
such as microvascular invasion and molecular signatures or DNA
analyses, which are powerful predictors of outcome, can be used
for staging, but depend upon tissue being available for analysis.
However, many patients are not subjected to biopsy or tumor
excision prior to treatment. Diagnostic laparoscopy and laparo-
scopic ultrasound increase the detection of multi-focal tumors,
portal hypertension and macrovascular invasion leading to a
change in tumor stage in up to 25% of patients.10 Whole body
positron emission tomography imaging with C11-acetate can be
useful to detect extra hepatic metastatic HCC.11 Thus, HCC
staging can vary widely based on the modalities used during the
pretreatment evaluation. This leads to erroneous treatment deci-
sions and ultimately to misleading and inaccurate treatment
results – especially for non operative therapies where anatomic
and biologic markers are not obtained prior to treatment. The
establishment of guidelines for optimal staging strategies, there-
fore, should allow for more precise comparisons between differing
treatment regimens.
Establishing the relative value of different
staging systems
There is consensus among experts that a HCC staging system
should be retrospectively and prospectively validated in the
patient populations where its use is proposed.1,4,7,9 Recent studies
comparing HCC staging systems to one another evaluated the
ability to discriminate outcomes in particular patient populations
subjected to specific therapies.12–21 Most staging systems studied
perform poorly when the study population includes a cohort of
patients with a wide spectrum of diseases and tumor stages.What
has emerged from these studies is an appreciation that the dis-
criminatory performance of various staging systems appears to
be treatment, stage and region specific.20–22 For example, the 6th
edition of AJCC TNM staging16,23 and the early prognosis score12,24
perform well for patients with early stage disease undergoing liver
resection or transplantation,12,16 whereas CLIP is predictive of
outcome in French patients in the palliative setting.25
Does tumor size matter?
The use of tumor size as a criterion for HCC staging systems
remains controversial. The 6th edition of AJCC TNM staging
found that tumor size alone did not predict survival after surgical
resection whereas advanced liver fibrosis did.26 Conversely, other
studies find size, even in early HCC, a reliable discriminator for
survival.12,24 For example, up to 25% of tumors less than 2 cm have
vascular invasion and poor survival after resection, ablation or
transplantation.12,24,27 Likewise, since the adoption of the Mazza-
ferro staging criteria, the use of tumor size to qualify patients
for liver transplantation remains contentious.28 While the risk
of vascular invasion increases with size, some tumors can grow
quite large without vascular invasion and these patients do
well after transplantation.29 This led to the development and use
of expanded criteria for selecting patients for liver transplanta-
tion,30,31 whereas other groups have explored the benefit of neo-
adjuvant tumor reduction strategies prior to transplantation.32
The emergence of biologic factors as important
prognostic variables in HCC
Recent studies show tumor biology and non tumor liver factors
are powerful predictors of outcome independent of tumor size.
Kaibori et al. reported that limited pre treatment hepatic func-
tional reserve in Japanese patients, measured by maximal extrac-
tion of glycolated serum albumin, independently predicts early
tumor recurrence and short survival even in patients with tumors
less than 2 cm.27 Some small HCCs have high metastatic potential
as shown by gene expression assessment through microarrays and
have an incidence of vascular invasion as high as 25%.33 Jonas
et al. recently reported that increased tumor DNA aneuploidy,
expressed as an index, is a more powerful prognostic indicator
than tumor size, Milan Criteria, or vascular invasion in cirrhotic
patients with HCC following liver transplantation.34 Poon and
colleagues reported that pretreatment serum VEGF levels inde-
pendently predicted overall and recurrence-free survival following
radiofrequency ablation.35 Collectively, these studies suggest liver
or tumor-related factors in patients with cirrhosis and HCC that
may influence the risk for recurrent disease.
Consensus statement
1. Based on current knowledge and experience, no single staging
system is applicable to all patients with HCC.
2. The use of regional staging system is discouraged because it
precludes comparison between centers.
3. In medical patients with advanced liver disease who are not
candidates for liver transplantation or resection, the Barcelona
Clinic Liver Cancer (BCLC) classification is appropriate.
4. There is significant heterogeneity within stage B and C of the
BCLC classification, thus resection may be considered for some
of these patients. Overall, BCLC criteria provide a reasonable
guide for treatment considering the caveat regarding stage B
and C patients.
5. The AJCC/UICC classification is valid for HCC staging based
on single and multicenter studies in the West and East, includ-
ing Japan and China for patients undergoing liver resection.
It is useful in patients with a normal liver or chronic liver
disease when coupled with the fibrosis score.
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6. Report pathological outcomes using the AJCC/UICC system
following resection or liver transplantation.
7. In the future, incorporation of recently described biomarkers
(VEGF plasma level and DNA index) may improve preopera-
tive staging.
Optimizing pretreatment imaging of HCC
Background
The incidence of HCC has doubled over the past 2 decades in the
US, currently estimated between 8,500–11,500 / year, and is pre-
dicted to increase over the next years mostly related to an increase
in chronic viral hepatitis C infection.36,37 Consequently, radiolo-
gists will encounter HCC during routine imaging with increasing
frequency. The hypervascular nature of HCC makes dual (arterial
and portal venous phases) or three-phase imaging (arterial, portal
venous and delayed phases) with dynamic intravenous contrast
injection a critical feature for the detection and characterization
of this tumor whether using computed tomography (CT) or
magnetic resonance imaging (MRI). Additionally, arterial
phase imaging withmultidetector row CT (MDCT) orMRI allows
a clear image of the vascular supply of the tumor and to the
liver. This is critical in patients who are candidates for transar-
terial chemoembolization (TACE), surgical resection or liver
transplantation.
Multidetector row computed tomography
MDCT is widely used for the detection of HCC before liver resec-
tion or transplantation.38 MDCT has several advantages including
rapid image acquisition, wide availability, high resolution images,
and multiphasic scanning. These features result in good accuracy
for HCC detection.38,39 However, MDCT is limited by the radia-
tion dose,40 which is non negligible in this patient population
where repeat imaging is common. In theory, double arterial phase
imaging with MDCT should improve HCC detection. However,
two prior studies39,41 did not show improved HCC detection using
MDCT compared to a conventional single arterial acquisition.
Murakami et al.42 used a triple arterial phase acquisition (at 20, 30
and 40 sec. after administration of contrast) with MDCT for HCC
detection, and showed that the second arterial phase showed the
best sensitivity compared with the early and late arterial phases for
HCC detection (mean area under the receiver operating curve:
0.84 vs. 0.56 (early) and 0.62 (late arterial phase). In our institu-
tions, we use 16- and 64-MDCT with a single arterial phase based
on the bolus track method.
Magnetic resonance imaging
Recent technological advances in hardware and software, together
with the development of a variety of contrast agents, have allowed
liver MRI to be considered the most accurate noninvasive imaging
technique for HCC detection. MRI lacks ionizing radiation, offers
higher contrast resolution and the possibility of performing mul-
tiparametric imaging, combining T1, T2, and diffusion-weighted
imaging with dynamic multiphasic imaging. State of the art MRI
now offers routinely thin 3D T1-weighted dynamic acquisitions.43
In addition, 3T MRI offers higher spatial resolution compared to
1.5T MRI, due to improved signal to noise ratio.44,45 With the use
of extracellular46,47 or liver-specific contrast agents such as super-
paramagnetic iron oxide (SPIO) particles48 or gadobenate dime-
glumine,49 MRI has a similar to higher diagnostic accuracy
compared to CT for HCC detection. Kim et al.48 compared the
accuracy of SPIO-enhanced MRI and 16-MDCT, and found
higher AUC for SPIO-enhanced MRI (0.90) compared to that for
MDCT (0.82), without significant difference. They found a trend
toward increased sensitivity on both a per-lesion and a per-patient
basis for SPIO-enhanced MRI (84.7% and 94.7%, respectively)
compared with MDCT (76.9% and 88.6%, respectively). Two
studies46,47 using extracellular agents showed better detection of
HCC nodules with MRI compared to CT. Burrel et al.47 showed a
sensitivity per-lesion of MRI of 76% vs. 61% for CT. However,
sensitivity of MRI for detection of small lesions is still low. In
the study by Burrel et al.,47 100% of nodules > 2 cm were detected,
compared to 84% for nodules between 1–2 cm, and 32% for
nodules less than 1 cm. A recently FDA approved liver-specific
gadolinium contrast agent called gadolinium ethoxybenzyl dieth-
ylenetriamine pentaacetic acid (Gd-EOB-DTPA or gadoxetic acid
disodium, Eovist (US) or Primovist (Europe, Asia) Bayer Health-
care) produces both dynamic and liver-specific hepatobiliary
images.50–60 This contrast agent is highly liver-specific, with
approximately 50% of the injected dose taken up by functioning
hepatocytes and excreted in bile, compared with an uptake of
3–5% for gadobenate dimeglumine.60 Results for detection of
HCC are so far promising.52 Few investigators have used SPIO
particles with or without the combined use of Gd-DTPA for HCC.
Using both Gd-DTPA and SPIO, Bhartia et al.62 demonstrated
78% sensitivity for detection of HCC.
Advanced MRI methods
These include image subtraction, diffusion-weighted imaging
(DWI), perfusion-weighted imaging (PWI) and magnetic reso-
nance elastography (MRE). Image subtraction is essential to
assess enhancement of T1 hyperintense liver nodules and for
the estimation of tumor necrosis after TACE.48,63 DWI can detect
tumor necrosis after TACE without the use of contrast media
and can be used to follow patients after TACE. DWI, PWI and
MRE show promising results for detection of background liver
fibrosis and cirrhosis.44,64,65 Finally, specific MRI sequences can
be used to accurately detect fat and iron in the liver and in liver
nodules.66
Consensus statement
1. The choice between dual-phase CT and MRI depends on local
expertise and availability. The utility of CT is limited by the
radiation dose. MRI has the best performance characteristics
for the detection of HCC. Ultrasound, particularly contrast
enhanced, could be useful for HCC screening when this exper-
tise is available.
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2. While MRI is superior to CT for HCC detection, both have
limited sensitivity and specificity for the detection of lesions
< 1 cm.
3. New MR liver specific agent (Gd-EOB-DTPA) is promising for
HCC detection and characterization.
4. Assessment of treatment response should not rely on lesion
size anymore. Image subtraction and diffusion-weighted MRI
are new emerging markers of the adequacy of local/loco-
regional and systemic treatments.
5. Background liver fibrosis and cirrhosis may be assessed with
functional MRI but this is still under investigation.
The role of portal vein embolization in
preparation for hepatic resection for HCC
Initially performed to prevent portal tumor extension of HCC,67
portal vein embolization (PVE) now is a well established method
to increase the volume and function of the non-embolized liver
prior tomajor hepatic resection. PVE leads to an increase in future
remnant liver (FLR) volume which is associated with improved
liver function measured by increased biliary excretion,67,68
technetium-99m-galactosyl human serum albumin uptake69 and
by significant improvement in the postoperative liver function
tests following PVE.70 PVE is used prior to extended hepatectomy
in patients without, or with limited liver disease and before major
hepatectomy in well compensated cirrhotic patients.71–74 Meta-
analysis of 37 studies including over 1,000 patients shows the
safety of PVE (morbidity 2.2%, mortality 0%), an increase in FLR
volume, and the ability to perform major resection with very low
risk of transient liver insufficiency (2.5%) or mortality from liver
failure (0.8%) despite extensive resections.75 FLR volume corre-
lates with FLR function, and importantly, the volume change after
PVE predicts functional outcome after resection.
Indications for PVE depend on factors that impact on the
volume of liver remnant needed for adequate post-hepatectomy
liver function. The absence or presence of underlying liver disease
and its severity impact on the need for PVE. Additional factors
include patient size (large patients require larger liver remnants
than smaller patients) and the extent and complexity of the
planned resection. One must consider all these factors in the
setting of the patient’s age and comorbidities that may influence
regeneration, such as diabetes. The volumetry should integrate
assessment of the actual FLR volume with patient size, so that the
standardized FLR volume expressed as a percentage of total liver
volume (%TLV) is used to determine the need for PVE. FLR
volume determined by three-dimensional CT imaging is stan-
dardized, typically to body surface area (BSA) or an estimated
total liver volume based on a BSA formula to generate a ‘standard-
ized’ FLR volume (i.e. volume standardized to the patient).70
The volume limit for safe resection likely varies from patient to
patient. Current guidelines evolved following careful analysis of
outcomes aftermajor hepatectomy. In patients with a normal liver,
PVE is indicated when the standardized FLR volume is  20%,
based on an analysis of complications in 42 patients, all of whom
had normal underlying liver and underwent right trisectionec-
tomy.76 The complication rate, intensive care unit stay and hospital
stay were prolonged in patients with a FLR volume  20% com-
pared to those with >20%. A subsequent study in patients with
normal liver confirmed this cutoff and showed that a FLR volume
increase > 5% indicates a low risk for liver failure after resection.77
Findings from two larger datasets validated these findings.78,79
Data from 301 consecutive right trisectionectomies in patients
with normal liver confirmed a clear correlation between postop-
erative liver insufficiency and FLR volume.78 Direct comparison
of patients with small (20% of TLV), intermediate (20.1 – 30%
of TLV) and large ( 30% of TLV) FLR volumes showed an
increased risk for liver insufficiency (and postoperative death) in
patients with small FLR volumes.78 Patients with pre-PVE FLR
volume 20% whose liver volumes increased to >20% post-PVE
underwent resection with complication, liver insufficiency, and
liver failure rates statistically equivalent to those who had a native
FLR volume > 20 or even > 30%. Their complication rate was
significantly lower than those operated with FLR volume < 20%.78
This study suggests that high risk, low FLR volume patients can be
converted by PVE to low risk (higher FLR volume) patients.
Among patients with intermediate liver disease, such as fibrosis
without cirrhosis, a larger FLR has been proposed (FLR 30% of
the TLV) to improve the safety of major resection.80,81 Similarly,
a larger FLR (>40% TLV) has been advocated for patients with
cirrhosis. Major resection in patients with cirrhosis is feasible
when liver function is preserved and portal hypertension (mani-
fest as splenomegaly, periesophageal varices and platelet count
< 100,000/microliter) is absent. PVE is indicated in most cirrhotic
patients where right hepatectomy is planned,71 or when the FLR is
 40% of the TLV.72,74 Leaving a smaller volume in patients with
cirrhosis results not only in liver insufficiency, but death from liver
failure after resection.74
A prospective, alternate allocation study71 demonstrated
that PVE is beneficial before right hepatectomy in patients with
cirrhosis. A significant decrease in postoperative complications,
duration of intensive care unit and total hospital stay occurred
in cirrhotic patients who underwent right hepatectomy after
PVE versus those who underwent right hepatectomy with cir-
rhosis without PVE. Patients in the PVE group had a mean FLR
of 35% – an indication for PVE based on the work of Kubota
et al.72 described above. The proportion of patients with one or
more complications, incidence of pulmonary complications,
ascites and liver failure was lower in the PVE group (all p < .05).
These authors also reinforced the initial finding of Hirai et al.69
that FLR growth in response to PVE is a predictor of favorable
postoperative outcomes.
A recent study compared 21 patients who underwent major
hepatectomy after PVE compared to 33 patients who underwent
hepatectomy without PVE.73 Overall complication rates were
similar between groups, but the major complication rate in the
non-PVE group was 35% compared to 10% in the PVE group
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(p = .028). There were no perioperative deaths in the PVE group
but six deaths (18%) in the non-PVE group (P = .038). Post-
operative mortality was related to liver insufficiency leading to
multiorgan failure in five; the sixth died with exacerbation of
preexisting renal disease. The two patients in the non-PVE group
who underwent preoperative volumetry did not experience com-
plications. Importantly, oncologic outcomes in these patients with
large and multifocal HCC were equivalent (5-year overall survival
rate 72% with PVE versus 54% without PVE; 5-year disease-free
survival rate 56% with PVE vs. 49% without PVE, both p = NS).73
Recently, the combination of TACE followed by PVE has been
proposed as a method to optimize liver growth and tumor treat-
ment.82,83 Hypertrophy rates for TACE + PVE exceed hypertrophy
rates for PVE only, likely because of occlusion of intratumoral
arteriovenous shunts by TACE prior to PVE.82 In addition, patho-
logic analysis showed a high response in the treated tumors after
this combination of embolizations.83 Though data are limited
with this combined approach, it appears to be an extremely effec-
tive method of reducing risk and optimizing outcome for major
resection in cirrhotic patients.
Contraindications to PVE include an adequate FLR based on the
listed criteria and tumor invasion of the portal vein on the side for
resection, as portal flow is already diverted. Relative contraindica-
tions include tumor extension to the FLR, uncorrectable coagul-
opathy,biliary dilatation in the FLR (if the biliary tree is obstructed,
drainage is recommended), portal hypertension and renal failure.
In conclusion, PVE is an effective method to increase the
volume and function of the FLR prior to major hepatectomy in a
spectrum of patients with normal, diseased, and cirrhotic livers.
With regard to patients with HCC and cirrhosis, PVE appears to
dramatically decrease risk for liver insufficiency and death after
liver resection, without negative impact on oncologic outcome.
TACE with PVE is emerging as a potential method to further
increase safety and improve outcomes following major resection
for HCC.
Consensus statement
1. Volumetry to evaluate the FLR is indicated if major hepatic
resection (resection involving more than four segments) is
planned or if the patient has underlying liver disease.
2. Preoperative PVE is appropriate when the FLR volume is
20% of TLV in patients with normal liver; 30% of TLV in
patients with liver injury; and 40% of TLV in patients with
well compensated hepatic fibrosis or cirrhosis.
3. Imaging is indicated 3–4 weeks after PVE to reassess liver
volume and degree of hypertrophy.
4. Resection is generally considered safest when FLR volume
reaches the target (20% to 40% depending on liver disease as
above), and degree of FLR hypertrophy is adequate (at least 5%
increase in FLR volume in normal liver and 10% increase in
FLR volume in cirrhosis).
5. Preoperative PVE is appropriate in patients with chronic liver
disease who are candidates for major hepatectomy. TACE fol-
lowed by PVE should be considered in patients with chronic
liver disease who are candidates for major hepatectomy.
6. The benefits of PVE are clearly established prior to major
hepatectomy in selected subsets of patients with and without
chronic liver disease. There is no role for a randomized trial of
PVE.
Defining criteria for resectability – tumor
characteristics and liver function
Background
HCC is the leading cause of cancer death in Asia, and its inci-
dence is rising in Western countries. Surgical resection remains
an important potentially curative option. Currently, only
10–25% of patients with HCC are resectable at the time of pre-
sentation. HCC primarily occurs in the setting of underlying
liver disease caused by chronic viral hepatitis infection, alcohol
use, genetic disorders, or environmental exposures. Because
most patients have underlying liver disease, pre-operative assess-
ment of liver function plays a central role in determining resec-
tability. In addition, various tumor-specific characteristics such
as tumor size, number, and the presence of vascular invasion
affect whether surgical resection is appropriate. In general,
patients with preserved liver function and small tumors are
candidates for resection. Similarly, patients with preserved liver
function and large tumors are usually candidates for resection,
but this depends on the location of the tumor(s) and the volume
of the FLR. In contrast, patients with an anticipated small FLR
or poor hepatic reserve have traditionally not been considered
candidates for surgical resection. The selection of patients with
HCC who should undergo surgical resection continues to evolve
and remains a source of some debate.
Liver function considerations
The spectrum of underlying liver disease can range from non-
bridging fibrosis to frank cirrhosis with associated severe fibrosis.
Preoperative sampling / biopsy of the non-tumorous liver may
occasionally be helpful in determining the extent of the chronic
liver disease. Unfortunately, the variability of fibrosis throughout
the liver is often a significant limitation in the preoperative assess-
ment of fibrosis by a liver biopsy.84 As such, routine biopsy of the
non-tumorous liver is unwarranted and not recommended.
The most commonly employed system for evaluating liver
function and the extent of cirrhosis is the Child-Pugh classifica-
tion scheme. The Child-Pugh score is a composite score including
three laboratory parameters (bilirubin level, albumin level, pro-
thrombin time) and two clinical factors (presence or absence of
ascites and encephalopathy). Surgical resection can be considered
in Child-Pugh A and very selected Child-Pugh B patients.85
However, while the Child-Pugh score is useful in assessing global
liver function, there is heterogeneity within Child-Pugh classes
and Child Pugh alone does not allow adequate selection of sur-
gical candidates. The risk of perioperative mortality increases
with the degree of hepatic functional impairment even in patients
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with well-compensated cirrhosis. A pre-operative MELD value
of greater than 10 has been shown to be associated a 90-day
mortality rate approaching 15–20%.86,87 In patients with well-
compensated cirrhosis, the MELD score is another useful tool
to select good candidates for major liver resection.
Other measures to evaluate hepatic metabolic function include
indocyanine green (ICG) retention rate, galactose elimination,
and aminopyrine clearance. Most experience with ICG comes
from Japan because this test is not widely used in the West.
Although retention rates at 15 minutes after intravenous injection
of ICG (0.5 mg/kg) can be useful prior to minor resection in
patients with cirrhosis, it provides an overall measurement of
function and does not differentiate between the liver planned for
resection and the anticipated liver remnant.
A number of groups have reported that the combination of
cirrhosis and portal hypertension is a relative contraindication for
resection of HCC.1,3 More recently, others have reported accept-
able results following resection of HCC in patients with portal
hypertension and cirrhosis.85,88 Selected patients with portal
hypertension can have good outcomes after minor resection
(two segments). On the other hand, patients with significant
underlying liver disease who require a major liver resection are
more likely to have significant postoperative morbidity and mor-
tality. Consideration for preoperative portal vein embolization
is appropriate and based on the size of the FLR.
Tumor characteristic considerations
Large HCCs – tumors with a diameter of 5 cm or more – are
relatively common, especially when screening is not routine.89 In
particular, the incidence of large HCCs is especially high in
patients under the age of 40 years. Patients with large HCCs are
generally not considered candidates for liver transplantation or
ablation.28 Hepatic resection, therefore, remains the only tenable
treatment option for these patients.90 However, some have sug-
gested that large tumor size should be a contraindication to liver
resection.91 Cited as contraindications are the technical challenges
of the operation and the worse prognosis associated with larger
tumors and the associated increased vascular invasion. More
recent data suggest, however, that patients with large tumors or
multi-nodular disease should be considered for surgical resection.
When resecting HCC > 10 cm, overall and disease-free 5 year
survival was reported to be 45% and 43%, respectively.92 In a
different series of 300 patients with HCC > 10 cm, the reported
peri-operative mortality was 5% with the majority of patients
having a major hepatic resection.93 While overall survival was
25–30%, patients with a solitary large HCCwithout vascular inva-
sion had a 5 year survival of 40–45%. In a third study, patients
with large HCC without vascular invasion had a reported survival
of >70%.94 In aggregate, these data emphasize that resection of
large HCCs is safe and the use of size alone to exclude patients
from surgical consideration is unwarranted.
Multi-focal HCC is associated with a poor prognosis,
recognized by its incorporation into most HCC staging and clas-
sification schemes. Five year survival rates in patients with com-
pensated cirrhosis who undergo resection of multinodular HCC
varies widely from 25% to 58% with recurrence rate ranging from
80 to 100%.85,95,96 Liver transplantation is the best treatment
option in patients with multinodular HCC and cirrhosis who
meet transplant criteria. Liver resection also can be offered in a
subset of patients with multinodular HCC outside the transplan-
tation criteria with good outcomes. The primary problem is
appropriate selection of patients with multinodular HCC since
few predictive factors of survival have been identified. Ishizawa
et al. showed that Child Pugh B status, a positive serology for
hepatitis C virus and microvascular invasion were associated with
a poor long term survival rate after resection in patients with
multinodular HCC.85 Thus, the heterogeneity of tumor size more
likely suggests intrahepatic metastases and advanced disease in
patients with multinodular HCC; patients with multiple lesions
of different size have poor outcomes and are not good candidates
for resection.85,95,96
Surgical resection for patients with HCC invading the portal
vein and/or the hepatic veins remains controversial. The results
of hepatic resection for HCC with major vascular invasion have
been disappointing, with 5-year survival rates of 10–11%.97 Ikai
et al.98 also reported that the degree of portal or hepatic vein
invasion significantly affected survival. Patients with tumor
thrombus distal to the second branch of the portal vein (Vp1) or
in the second branch of the portal vein (Vp2) had a significantly
longer survival than patients with tumor thrombus either in the
first branch of the portal vein (Vp3) or in the portal trunk (Vp4).
Similarly, patients with tumor thrombus in a tributary of the
main hepatic vein (Vv1) had a better prognosis than patients
with invasion of the main hepatic vein (Vv2). In the same study,98
patients with Vp3 and Vv2 vascular invasion had 5-year median
survival durations of 7% and 11%, respectively. Data from an
international cooperative group99 reported a 5-year survival rate
of 10% for resected patients with Vp3 or Vv2 tumor thrombus,
similar to the rates in earlier reports by Poon and Fan97 and Ikai
et al.98 As such, while not a formal contraindication to surgery,
the benefit of resection is limited to highly selected cases. In
general, surgical resection in patients with vascular invasion with
extension to the main portal trunk or vena cava is not likely to
be beneficial.
Consensus statement
1. It is important to consider the severity of any underlying liver
disease when assessing resectability. The MELD score is helpful
for selecting patients with compensated cirrhosis as candidates
for major hepatic resection. The indication for preoperative
portal vein embolization is based on volumetric measurements
of the FLR.
2. While minor resection is not contraindicated in selected
Child-Pugh A patients with portal hypertension, the presence
of ascites and a serum bilirubin > 2 mg/dL are contraindica-
tions for such resections. Major liver resection may be consid-
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ered in patients with Child – Pugh A cirrhosis without portal
hypertension and bilirubin serum level  1 mg/dL in patients
without biliary obstruction. ICG R15, when available, can be
useful for the selection of patients with advanced liver disease
who are candidates for minor liver resection.
3. Strict tumor size criteria to consider resection are unwar-
ranted. Large (>5 cm) tumor size is not an absolute contrain-
dication for resection.
4. Patients withmulti-focal tumors who have adequate liver func-
tion / FLR should be considered for resection. Patients with
multi-nodular disease, however, have a particularly high risk
of recurrence. As such, transplantation is a better option for
patients with multinodular disease and chronic liver disease
who meet Milan criteria.
5. While major vascular invasion of the ipsilateral hepatic or
portal vein is not an absolute contraindication to surgery, the
long-term benefit of resection for patients with main portal
vein or caval tumor thrombus is very limited. Resection in
these patients is considered a palliative procedure and is rarely
indicated.
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